GALECTIN-7 AS A BIOMARKER FOR DIAGNOSIS, PROGNOSIS AND MONITORING OF OVARIAN AND RECTAL CANCER
First Claim
Patent Images
1. A method for determining whether a subject has ovarian cancer or a predisposition to develop ovarian cancer, said method comprising:
- (i) measuring the level of expression of Galectin-7 in an ovarian cell and/or tissue sample from said subject;
(ii) comparing said level of expression to a control level; and
(iii) determining whether said subject has ovarian cancer or a predisposition to develop ovarian cancer based on said comparison.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods, kits and systems for the diagnosis, prognosis and monitoring of ovarian cancer and rectal cancer are described. The methods, kits and systems are based on the detection of the lectin Galectin-7 in samples obtained from subjects.
-
Citations
34 Claims
-
1. A method for determining whether a subject has ovarian cancer or a predisposition to develop ovarian cancer, said method comprising:
-
(i) measuring the level of expression of Galectin-7 in an ovarian cell and/or tissue sample from said subject; (ii) comparing said level of expression to a control level; and (iii) determining whether said subject has ovarian cancer or a predisposition to develop ovarian cancer based on said comparison. - View Dependent Claims (2, 4, 6, 7, 8, 9, 10)
-
-
3. (canceled)
-
5. (canceled)
-
11. A method for determining whether a subject has rectal cancer or a predisposition to develop rectal cancer, said method comprising:
-
(iv) measuring the level of expression of Galectin-7 in a rectal cell and/or tissue sample from said subject; (v) comparing said level of expression to a control level; and (vi) determining whether said subject has rectal cancer or a predisposition to develop rectal cancer based on said comparison. - View Dependent Claims (12, 14, 16, 17, 18)
-
-
13. (canceled)
-
15. (canceled)
-
19. A method for monitoring the progression of ovarian or rectal cancer in a subject, the method comprising:
-
(i) measuring the level of expression of Galectin-7 in a first ovarian or rectal cell and/or tissue sample from said subject at a first time point; (ii) measuring the level of expression of Galectin-7 in a second ovarian or rectal cell and/or tissue sample from said subject at a later time point; (iii) wherein (a) a level of expression of Galectin-7 that is higher in said second sample relative to said first sample is indicative that said ovarian or rectal cancer has progressed;
(b) a level of expression of Galectin-7 that is lower in said second sample relative to said first sample is indicative that said ovarian or rectal cancer has regressed;
or (c) a level of expression of Galectin-7 that is similar in said second sample relative to said first sample is indicative that said ovarian or rectal cancer is stable. - View Dependent Claims (20, 22, 23)
-
-
21. (canceled)
-
24-30. -30. (canceled)
-
31. An ovarian or rectal cancer diagnostic system comprising (i) an ovarian or rectal cell and/or tissue sample;
- (ii) a Galectin-7 binding reagent; and
(iii) a device for detecting the presence and/or amount of Galectin-7/Galectin-7 binding reagent complexes.
- (ii) a Galectin-7 binding reagent; and
-
32. (canceled)
-
33. A computer-readable medium comprising code for controlling one or more processors to classify whether an ovarian or rectal cell and/or tissue sample from an subject is associated with ovarian or rectal cancer, said code comprising:
- instructions to apply a statistical process to a data set comprising a Galectin-7 profile to produce a statistically derived decision classifying said sample as an ovarian or rectal cancer sample or non-ovarian or rectal cancer sample based upon said Galectin-7 profile, wherein said Galectin-7 profile indicates the level of Galectin-7 in said ovarian or rectal cell and/or tissue sample.
-
34-37. -37. (canceled)
Specification